Bal Pharma Limited (BALPHARMA.BO)
INR 111.73
(1.87%)
INR 111.73
(1.87%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 73.92 Million INR | 187.43% |
| 2022 | 25.71 Million INR | -54.17% |
| 2021 | 56.11 Million INR | 18.33% |
| 2020 | 47.42 Million INR | 138.81% |
| 2019 | -122.18 Million INR | -422.55% |
| 2018 | 37.88 Million INR | 36.16% |
| 2017 | 27.82 Million INR | 58.32% |
| 2016 | 17.57 Million INR | 25.04% |
| 2015 | 14.05 Million INR | -61.26% |
| 2014 | 36.27 Million INR | -28.48% |
| 2013 | 50.72 Million INR | 18.41% |
| 2012 | 42.83 Million INR | 14.02% |
| 2011 | 37.56 Million INR | 695.46% |
| 2010 | 4.72 Million INR | 133.05% |
| 2009 | -14.28 Million INR | -147.74% |
| 2008 | 29.92 Million INR | 4.75% |
| 2007 | 28.57 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 2.59 Million INR | -95.27% |
| 2023 Q1 | 11.95 Million INR | -25.32% |
| 2023 Q2 | 9.45 Million INR | -20.88% |
| 2023 Q3 | 8.88 Million INR | -6.01% |
| 2023 Q4 | 54.73 Million INR | 515.74% |
| 2023 FY | 73.92 Million INR | 187.43% |
| 2022 FY | 25.71 Million INR | -54.17% |
| 2022 Q4 | 16 Million INR | 178.38% |
| 2022 Q3 | 5.74 Million INR | 403.86% |
| 2022 Q2 | 1.14 Million INR | -91.89% |
| 2022 Q1 | 14.07 Million INR | -28.6% |
| 2021 Q4 | 19.7 Million INR | 208.16% |
| 2021 Q3 | 6.39 Million INR | -53.63% |
| 2021 Q2 | 13.79 Million INR | -16.37% |
| 2021 FY | 56.11 Million INR | 18.33% |
| 2021 Q1 | 16.49 Million INR | -53.91% |
| 2020 Q2 | 4.24 Million INR | 0.43% |
| 2020 FY | 47.42 Million INR | 138.81% |
| 2020 Q3 | 3.17 Million INR | -25.31% |
| 2020 Q4 | 35.78 Million INR | 1028.8% |
| 2020 Q1 | 4.22 Million INR | 110.4% |
| 2019 FY | -122.18 Million INR | -422.55% |
| 2019 Q2 | -18.33 Million INR | 20.3% |
| 2019 Q1 | -23 Million INR | -178.14% |
| 2019 Q3 | -35.69 Million INR | -94.66% |
| 2019 Q4 | -40.62 Million INR | -13.83% |
| 2018 Q4 | 29.44 Million INR | 85.86% |
| 2018 Q2 | -7.54 Million INR | -147.64% |
| 2018 FY | 37.88 Million INR | 36.16% |
| 2018 Q1 | 15.84 Million INR | 562.48% |
| 2018 Q3 | 15.84 Million INR | 309.91% |
| 2017 FY | 27.82 Million INR | 58.32% |
| 2017 Q4 | -3.42 Million INR | 0.0% |
| 2016 Q3 | 6.07 Million INR | -65.27% |
| 2016 FY | 17.57 Million INR | 25.04% |
| 2016 Q4 | -18.26 Million INR | -400.46% |
| 2016 Q2 | 17.5 Million INR | 246.16% |
| 2016 Q1 | 5.05 Million INR | 119.32% |
| 2015 Q4 | -26.16 Million INR | -238.41% |
| 2015 FY | 14.05 Million INR | -61.26% |
| 2015 Q1 | -31.47 Million INR | -2045.51% |
| 2015 Q2 | 20.47 Million INR | 165.06% |
| 2015 Q3 | 18.9 Million INR | -7.68% |
| 2014 Q1 | 9.84 Million INR | -27.53% |
| 2014 Q4 | 1.61 Million INR | -79.37% |
| 2014 Q3 | 7.84 Million INR | -53.81% |
| 2014 FY | 36.27 Million INR | -28.48% |
| 2014 Q2 | 16.97 Million INR | 72.52% |
| 2013 Q1 | 9.14 Million INR | -56.9% |
| 2013 Q4 | 13.57 Million INR | -2.34% |
| 2013 FY | 50.72 Million INR | 18.41% |
| 2013 Q2 | 14.09 Million INR | 54.14% |
| 2013 Q3 | 13.9 Million INR | -1.36% |
| 2012 Q2 | 9.28 Million INR | 383.08% |
| 2012 Q1 | 1.92 Million INR | -88.53% |
| 2012 Q3 | 10.41 Million INR | 12.23% |
| 2012 Q4 | 21.21 Million INR | 103.74% |
| 2012 FY | 42.83 Million INR | 14.02% |
| 2011 Q3 | 13.08 Million INR | 104.31% |
| 2011 Q4 | 16.74 Million INR | 28.02% |
| 2011 FY | 37.56 Million INR | 695.46% |
| 2011 Q2 | 6.4 Million INR | 0.0% |
| 2010 FY | 4.72 Million INR | 133.05% |
| 2009 FY | -14.28 Million INR | -147.74% |
| 2008 FY | 29.92 Million INR | 4.75% |
| 2007 FY | 28.57 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 98.8% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 99.767% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 98.43% |
| Granules India Limited | 4.05 Billion INR | 98.176% |
| Indoco Remedies Limited | 984.6 Million INR | 92.492% |
| Achyut Healthcare Limited | 5.73 Million INR | -1189.637% |
| Ajanta Pharma Limited | 8.16 Billion INR | 99.094% |
| Alkem Laboratories Limited | 17.95 Billion INR | 99.588% |
| Alpa Laboratories Limited | 167.76 Million INR | 55.937% |
| Brooks Laboratories Limited | -195.91 Million INR | 137.731% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | 95.423% |
| Bajaj HealthCare Limited | -837.93 Million INR | 108.822% |
| Bliss GVS Pharma Limited | 754.54 Million INR | 90.203% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 99.867% |
| Eris Lifesciences Limited | 3.91 Billion INR | 98.114% |
| FDC Limited | 3.05 Billion INR | 97.578% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 100.492% |
| Gufic Biosciences Limited | 861.35 Million INR | 91.418% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 98.244% |
| Ipca Laboratories Limited | 5.47 Billion INR | 98.649% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | 67.092% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 137.47% |
| Lasa Supergenerics Limited | -217.3 Million INR | 134.017% |
| Laurus Labs Limited | 1.6 Billion INR | 95.396% |
| Lupin Limited | 19.14 Billion INR | 99.614% |
| Mankind Pharma Limited | 19.12 Billion INR | 99.614% |
| Medicamen Biotech Limited | 109.31 Million INR | 32.374% |
| Medico Remedies Limited | 82.9 Million INR | 10.84% |
| Megasoft Limited | -127.46 Million INR | 157.994% |
| NATCO Pharma Limited | 13.88 Billion INR | 99.468% |
| Piramal Pharma Limited | 178.2 Million INR | 58.517% |
| RPG Life Sciences Limited | 876.6 Million INR | 91.567% |
| Sigachi Industries Limited | 571.8 Million INR | 87.072% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 99.923% |
| Suven Pharmaceuticals Limited | 3 Billion INR | 97.538% |
| Syncom Formulations (India) Limited | 253.14 Million INR | 70.798% |
| Unichem Laboratories Limited | -704.74 Million INR | 110.489% |
| Wanbury Limited | 559.56 Million INR | 86.789% |
| Windlas Biotech Limited | 581.87 Million INR | 87.296% |
| ZIM Laboratories Limited | 172.46 Million INR | 57.138% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 99.808% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 101.909% |
| Divi's Laboratories Limited | 16 Billion INR | 99.538% |
| Hester Biosciences Limited | 188.89 Million INR | 60.865% |
| Procter & Gamble Health Limited | 2 Billion INR | 96.322% |
| Amrutanjan Health Care Limited | 449.72 Million INR | 83.563% |
| Strides Pharma Science Limited | -706.14 Million INR | 110.468% |
| Venus Remedies Limited | 284.9 Million INR | 74.054% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | 96.592% |
| Nectar Lifesciences Limited | 49.95 Million INR | -47.992% |
| Shilpa Medicare Limited | 318.74 Million INR | 76.808% |
| Aarti Drugs Limited | 1.71 Billion INR | 95.688% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | 94.501% |
| Suven Life Sciences Limited | -1.05 Billion INR | 107.035% |
| Ind-Swift Limited | 142.31 Million INR | 48.057% |
| Valiant Laboratories Limited | 3.19 Million INR | -2212.954% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 98.662% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 101.303% |
| Themis Medicare Limited | 435.23 Million INR | 83.016% |
| Hikal Limited | 696.02 Million INR | 89.379% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 99.554% |
| Sequent Scientific Limited | -358.69 Million INR | 120.609% |
| Novartis India Limited | 851.9 Million INR | 91.323% |
| Wockhardt Limited | -4.63 Billion INR | 101.597% |
| Jubilant Pharmova Limited | 771 Million INR | 90.412% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | -942.329% |
| Neuland Laboratories Limited | 3 Billion INR | 97.537% |
| Morepen Laboratories Limited | 961.59 Million INR | 92.313% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | 49.373% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | 181.486% |